Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Arvinas (ARVN) and the $14 Price Target: Is +106% Upside Realistic?

Arvinas (ARVN) and the $14 Price Target: Is +106% Upside Realistic?

Key Takeaways

  • The central price target used here is $14, the arithmetic mean of nine current, individually attributed analyst targets issued between August and November 2026, rounded from roughly $13.80.
  • With shares trading near $6.80, reaching $14 would require a gain of roughly 106% — a very large move by any standard.
  • The target range is wide, from about $8 to $21 (extending to $6 at the most bearish firm), reflecting genuine disagreement over Arvinas' post-approval outlook.
  • Supporting factors: the first FDA-approved PROTAC therapy, a validated protein-degradation platform, and a multiyear cash runway.
  • Biggest risks: lumpy, milestone-driven revenue, intense competition in breast cancer, and a recent wave of downgrades and price-target cuts.
  • For more detail, explore Arvinas' Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

Arvinas, Inc. (ARVN) is a New Haven, Connecticut-based clinical-stage biotechnology company and a pioneer in targeted protein degradation through its PROTAC (PROteolysis TArgeting Chimera) platform. Its lead program, VEPPANU (vepdegestrant), was approved by the FDA in May 2026 for ESR1-mutated advanced breast cancer.

A review of nine current, individually attributed sell-side targets — spanning Barclays ($20), Citigroup ($21), Evercore ISI ($14), BofA Securities ($15), H.C. Wainwright ($13), Wedbush ($12), Wells Fargo ($11), Morgan Stanley ($10), and Leerink Partners ($8) — produces an arithmetic mean of about $13.80, rounded to a $14 central target. The range is unusually wide, from $8 to $21, and Goldman Sachs has been among the most cautious with a $6 target. Notably, these targets have been falling: Citigroup trimmed its target from $24 to $21, Wells Fargo downgraded the stock to a hold-equivalent rating, and several firms lowered targets after third-quarter results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Bullish analysts emphasize the validated degrader platform and the value of the Rigel licensing deal, while cautious analysts point to weak commercial prospects and a shrinking near-term pipeline. This spread explains why the average analyst price target sits far above the current price even as ratings have drifted toward "hold."

Current Market Position and Path Toward the Target

Arvinas shares closed near $6.80 in mid-November 2026, not far above a 52-week range of roughly $6.41 to $13.83 and down more than 40% over the trailing year. Reaching the $14 central target would require an approximate 106% advance — a very large move that would effectively restore the stock to its early-2026 levels before the post-approval decline.

The company's finances are unusual for a biotech: revenue is milestone-driven and lumpy, with Q2 2026 revenue of $249.7 million (including a $50 million Pfizer milestone) collapsing to $0.5 million in Q3 2026. Arvinas reported a Q3 net loss of roughly $53.9 million but holds more than $550 million in cash, funding operations into the second half of 2028. With a market capitalization near $500 million, the stock trades close to its net cash position, which some investors view as a valuation floor.

What Could Support a Move Toward the Target

  • Platform validation: VEPPANU is the first FDA-approved PROTAC degrader, de-risking the technology class for future programs.
  • Pipeline catalysts: Preliminary ARV-393 (zaloblideg, a BCL6 degrader) monotherapy data are expected at the ASH meeting in late 2026, alongside ARV-102 in neurodegeneration and ARV-6723 in immuno-oncology.
  • Balance sheet: More than $550 million in cash limits near-term dilution and financing risk.
  • Valuation near cash: The depressed share price means any clinical or partnership progress could support a sharp re-rating.

What Could Prevent the Target From Being Reached

  • Competitive pressure: Eli Lilly (LLY)'s ilunestrant showed a similar progression-free survival benefit in the ESR1-mutated setting, blunting VEPPANU's commercial differentiation.
  • Revenue uncertainty: Because Arvinas licensed VEPPANU to Rigel Pharmaceuticals (RIGL) with Pfizer (PFE), future income is largely milestone- and royalty-dependent rather than recurring product sales.
  • Shrinking pipeline investment: The company suspended internal investment in the KRAS G12D program (ARV-806), narrowing near-term optionality.
  • Sentiment deterioration: The string of downgrades and target cuts reflects waning Street confidence that near-term value will be realized.

Technical Levels and Market Structure

Arvinas has been in a persistent downtrend, now trading within a few percent of its 52-week low near $6.41. That level is the nearest meaningful support. On the upside, former support around $8 to $9, the psychologically important $10 level, and the 52-week high near $13.83 all stand between the current price and the $14 target. A sustained move toward the target would require clearing each of these resistance zones, which have coincided with earlier failed rebounds. From what I see, the technical setup remains challenging until those levels are cleared.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a 12-month research horizon, though individual firms vary. Investors focused on this $14 stock price target should watch the ASH 2026 presentation of ARV-393 data, any ARV-102 neurological readouts, VEPPANU launch progress reported by Rigel, quarterly cash burn, and any new partnership or licensing activity. Further analyst revisions — up or down — following these catalysts will likely move the consensus materially, given how wide the current range already is.

AI Daily Buy/Sell Signals

I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. The tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For investors tracking a volatile name like Arvinas, automated signal generation can help flag momentum changes as clinical and commercial catalysts unfold.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARVN

ARVN's Indicator enters downward trend

The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 260 similar instances where the Aroon Indicator formed such a pattern. In 226 of the 260 cases the stock moved lower. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 55 cases where ARVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +7.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.592). P/E Ratio (21.367) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (442.120).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapies to degrade disease-causing proteins

Industry Biotechnology

Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
246
Web
https://www.arvinas.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.